standard second-line chemotherapy

Phase 2Small molecule

standard second-line chemotherapy is one of 29 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 3

45 2

Braftovi

Pfizer

Phase 3

11 3

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 4

Fusilev

DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Phase 3

1 5

Cosela

PPharmacosmos A/S

Phase 3

1 6

Vatalanib

Novartis

Phase 3

2 7

PF-08634404

Pfizer

Phase 3

—8

Brivanib Alaninate

GGynecologic Oncology Group

Phase 3

1 9

FOLFOX 2d

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

Napabucasin

Sumitomo Pharma America, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Chemotherapy

NCT06838338

Clinical

Trials by Indication[1]

Chemotherapy1 trial

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

Active, not recruiting·JJian Li·Phase 1·NCT06838338·30 enrolled

Metastatic Colorectal Cancer1 trial

Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer

Unknown status·LLiqiang Zhong·Phase 2·NCT03412994·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for standard second-line chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — standard second-line chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for standard second-line chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jian Li company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: JJian Li

standard second-line chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Chemotherapy1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News